Yuchen Ding
Biographic Data
| ID | 7790143 |
|---|---|
| NAME | Yuchen Ding |
| GIVEN NAMES | Yuchen |
| FAMILY NAME | Ding |
| SIGNATURE | DING Y |
| AFFILIATIONS | Nantong University |
| ORCID | 0000-0002-6539-5213 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Creative disruption or destructive inequality? Firm-level evidence on AI adoption and employment dynamics
This study investigates the employment effects of artificial intelligence (AI) adoption at the firm level in China’s manufacturing sector. Drawing on a panel of over 1700 listed firms from 2001 to 2024, we construct multiple measures of AI adoption using R&D investment, patent activity, and textual disclosures. Empirical analyses employing fixed-effects regressions, mediation and moderation models, and dynamic specifications show that AI adoption…
Preferences for public health insurance coverage of new anticancer drugs
Health insurance policymakers need to consider the affordability, comparative survival benefits, comparative safety, and comparative patient-reported outcomes of new anticancer drugs. The findings also highlight the need to ensure affordability for older patients, low-income patients, and patients with advanced cancer
From west to east
The epidemiology of inflammatory bowel disease (IBD) has changed dramatically worldwide. This survey analyzed patterns and trends in the burden of IBD to aid future decision making. The incidence, prevalence, mortality, and disability-adjusted life year data for IBD were derived from the GBD (Global Burden of Disease) study. In 2021, there were 3,830,119 cases of IBD worldwide, including 375,140 new cases, 42,423 IBD-related deaths, and 1,510,784…
No prominent works on this page.
Preferences for public health insurance coverage of new anticancer drugs
Health insurance policymakers need to consider the affordability, comparative survival benefits, comparative safety, and comparative patient-reported outcomes of new anticancer drugs. The findings also highlight the need to ensure affordability for older patients, low-income patients, and patients with advanced cancer
From west to east
The epidemiology of inflammatory bowel disease (IBD) has changed dramatically worldwide. This survey analyzed patterns and trends in the burden of IBD to aid future decision making. The incidence, prevalence, mortality, and disability-adjusted life year data for IBD were derived from the GBD (Global Burden of Disease) study. In 2021, there were 3,830,119 cases of IBD worldwide, including 375,140 new cases, 42,423 IBD-related deaths, and 1,510,784…
Creative disruption or destructive inequality? Firm-level evidence on AI adoption and employment dynamics
This study investigates the employment effects of artificial intelligence (AI) adoption at the firm level in China’s manufacturing sector. Drawing on a panel of over 1700 listed firms from 2001 to 2024, we construct multiple measures of AI adoption using R&D investment, patent activity, and textual disclosures. Empirical analyses employing fixed-effects regressions, mediation and moderation models, and dynamic specifications show that AI adoption…
Biostatistics (2 works) · Environmental health (2 works) · Epidemiology (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Pathology (2 works) · Public health (2 works) · Actuarial science (1 work) · Burden of disease (1 work) · China (1 work)